JP2022172244A5 - - Google Patents

Download PDF

Info

Publication number
JP2022172244A5
JP2022172244A5 JP2022137454A JP2022137454A JP2022172244A5 JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5 JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5
Authority
JP
Japan
Prior art keywords
polypeptide
hcv
genotype
hcv genotype
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022137454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022172244A (ja
Filing date
Publication date
Priority claimed from JP2021001926A external-priority patent/JP2021059596A/ja
Application filed filed Critical
Publication of JP2022172244A publication Critical patent/JP2022172244A/ja
Publication of JP2022172244A5 publication Critical patent/JP2022172244A5/ja
Priority to JP2024130501A priority Critical patent/JP2024156917A/ja
Pending legal-status Critical Current

Links

JP2022137454A 2013-05-15 2022-08-31 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 Pending JP2022172244A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024130501A JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US61/823,712 2013-05-15
US201361887229P 2013-10-04 2013-10-04
US61/887,229 2013-10-04
JP2021001926A JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021001926A Division JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024130501A Division JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Publications (2)

Publication Number Publication Date
JP2022172244A JP2022172244A (ja) 2022-11-15
JP2022172244A5 true JP2022172244A5 (https=) 2023-07-28

Family

ID=54054625

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016513459A Withdrawn JP2016520077A (ja) 2013-05-15 2014-05-15 Ｅ１ｅ２ｈｃｖワクチン及び使用方法
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2022137454A Pending JP2022172244A (ja) 2013-05-15 2022-08-31 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016513459A Withdrawn JP2016520077A (ja) 2013-05-15 2014-05-15 Ｅ１ｅ２ｈｃｖワクチン及び使用方法
JP2019087976A Withdrawn JP2019142962A (ja) 2013-05-15 2019-05-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法
JP2021001926A Pending JP2021059596A (ja) 2013-05-15 2021-01-08 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024130501A Pending JP2024156917A (ja) 2013-05-15 2024-08-07 Ｅ１ｅ２ ｈｃｖワクチン及び使用方法

Country Status (8)

Country Link
US (3) US20210145963A9 (https=)
EP (2) EP3689375A1 (https=)
JP (5) JP2016520077A (https=)
CN (2) CN105263517B (https=)
AU (3) AU2014385320B2 (https=)
CA (1) CA2909586C (https=)
CL (1) CL2015003333A1 (https=)
WO (1) WO2015132619A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4491735A3 (en) * 2015-10-08 2025-04-16 The Governors of the University of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
WO2018068132A1 (en) 2016-10-11 2018-04-19 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
EP3765075A4 (en) * 2018-03-16 2021-12-08 The Governors of the University of Alberta HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF
WO2025222304A1 (en) * 2024-04-26 2025-10-30 The Governors Of The University Of Alberta Hcv genotype3 e2 envelope protein for neutralizing infectivity of hcv strains

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
SK15762003A3 (sk) * 2001-06-29 2005-01-03 Chiron Corporation Kompozícia vakcíny HCV E1E2
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
US8603468B2 (en) * 2007-11-06 2013-12-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Neutralization of HCV
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022172244A5 (https=)
JP2023512519A5 (https=)
JP2017515508A5 (https=)
JP2019519252A5 (https=)
EP1523557A2 (en) Antigens encoded by alternative reading frame from pathogenic viruses
JP2003526662A5 (https=)
JP2012503011A5 (ja) 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物
JP2010500399A5 (https=)
JP2019151636A5 (https=)
JP2019526580A5 (https=)
JP2009511084A5 (https=)
JP2014523878A5 (https=)
JP2010530362A5 (https=)
Noordeen Hepatitis B virus infection: An insight into infection outcomes and recent treatment options
JP2022514759A5 (https=)
JP2019142962A5 (https=)
JP2004527524A5 (https=)
JP2022521410A5 (https=)
JP2008514203A5 (https=)
JP2006502228A5 (https=)
JP2009501001A5 (https=)
JP2003508409A (ja) 慢性ウイルス感染に対するペプチド混合物及びワクチン
JP2007504112A5 (https=)
BRPI0414026A (pt) composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b
JP2016520077A5 (https=)